Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin
kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
cDNA cloning and heterologous expression of a wheat proteinase inhibitor of subtilisin
and chymotrypsin (WSCI) that interferes with digestive enzymes of insect pests.
KEY WORDS: Perkinsus marinus, subtilisin
, serine protease, real-time PCR, Crassostrea virginica, Crassostrea gigas, Crassostrea ariakensis
Nevertheless, Chen and Arnold  have adapted enzymes to these environments by improving the activity of Subtilisin
E by three cycles of error-prone PCR to obtain an enzyme that is 256 times more efficient than the native parent in a solution containing 60 percent DMF.
(3), chymosin (4), and interleukin-1[beta] ( 5).
In nature, subtilisin
breaks apart the chains of amino acids that make up certain proteins.
In the case of PrioCHECK Trichinella AAD, this enzyme is a subtilisin
Lipids: All eyes are on ongoing pivotal phase III randomized clinical outcome trials of three monoclonal antibodies that inhibit proprotein convertase subtilisin
kexin type 9 (PCSK9): the 22,500-patient FOURIER trial of evolocumab, which includes 9,000 patients older than 65 years; the 18,000-patient ODYSSEY Outcomes trial of alirocumab; and the SPIRE-1 and SPIRE-2 trials of bococizumab totaling 18,300 patients.
Russell and co-worker Darrell Williams converted the enzyme subtilisin
into a "biomonomer" that can link up with other monomers.
OSLER (Open-Label Study of Long-Term Evaluation Against LDL Cholesterol) included 4,465 patients who had completed one of a dozen earlier phase II or III studies of evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin
kexin type 9 (PCSK9), and were then randomized 2:1 to 1 year of open-label evolocumab administered subcutaneously at either 140 mg every 2 weeks or 420 mg once monthly plus standard lipid lowering, or to standard lipid lowering alone, generally with moderate- or highdose statins.
Circulating proprotein convertase subtilisin
kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
REPATHA(TM) is an antibody that targets PCSK9 (proprotein convertase subtilisin
kexin type 9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C) from the blood.